CO7091176A2 - Diagnóstico farmacéutico - Google Patents

Diagnóstico farmacéutico

Info

Publication number
CO7091176A2
CO7091176A2 CO14215143A CO14215143A CO7091176A2 CO 7091176 A2 CO7091176 A2 CO 7091176A2 CO 14215143 A CO14215143 A CO 14215143A CO 14215143 A CO14215143 A CO 14215143A CO 7091176 A2 CO7091176 A2 CO 7091176A2
Authority
CO
Colombia
Prior art keywords
diagnosis
pharmaceutical
pharmaceutical diagnosis
Prior art date
Application number
CO14215143A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Furet
Christine Fritsch
Sauveur-Michel Maira
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48083130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7091176(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO7091176A2 publication Critical patent/CO7091176A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CO14215143A 2012-03-29 2014-09-29 Diagnóstico farmacéutico CO7091176A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261617284P 2012-03-29 2012-03-29
US201361767848P 2013-02-22 2013-02-22

Publications (1)

Publication Number Publication Date
CO7091176A2 true CO7091176A2 (es) 2014-10-21

Family

ID=48083130

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14215143A CO7091176A2 (es) 2012-03-29 2014-09-29 Diagnóstico farmacéutico

Country Status (25)

Country Link
US (1) US9795596B2 (enExample)
EP (1) EP2830621B1 (enExample)
JP (1) JP6224067B2 (enExample)
KR (1) KR20140138771A (enExample)
CN (1) CN104271136A (enExample)
AR (1) AR090544A1 (enExample)
AU (1) AU2013241752B2 (enExample)
BR (1) BR112014023530A2 (enExample)
CA (1) CA2866127A1 (enExample)
CL (1) CL2014002576A1 (enExample)
CO (1) CO7091176A2 (enExample)
EA (1) EA028984B1 (enExample)
EC (1) ECSP14025016A (enExample)
ES (1) ES2845560T3 (enExample)
GT (1) GT201400206A (enExample)
HK (1) HK1200723A1 (enExample)
IL (1) IL234658B (enExample)
IN (1) IN2014DN08970A (enExample)
MX (1) MX2014011682A (enExample)
NZ (1) NZ628596A (enExample)
PH (1) PH12014502168A1 (enExample)
SG (2) SG10201608001RA (enExample)
TW (1) TW201345525A (enExample)
WO (1) WO2013144249A1 (enExample)
ZA (1) ZA201405938B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014229240B2 (en) * 2013-03-15 2017-06-15 Novartis Ag Biomarkers of tumor pharmacodynamic response
EP3140427B1 (en) * 2014-05-09 2020-10-14 Memorial Sloan Kettering Cancer Center Biomarkers for response to pi3k inhibitors
KR102486126B1 (ko) * 2014-10-03 2023-01-09 노파르티스 아게 알펠리십을 포함하는 제약 조성물
US20180353515A1 (en) * 2015-12-03 2018-12-13 Novartis Ag Treatment of cancer with a pi3k inhibitor in a patient presselected for having a pik3ca mutation in the ctdna
WO2019199860A1 (en) * 2018-04-09 2019-10-17 The Research Foundation For The State University Of New York Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
EP0425563B1 (en) 1988-07-20 1996-05-15 David Segev Process for amplifying and detecting nucleic acid sequences
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
EP2307414A4 (en) 2008-07-07 2011-10-26 Xcovery Holding Co Llc SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Also Published As

Publication number Publication date
AU2013241752B2 (en) 2016-07-07
SG10201608001RA (en) 2016-11-29
US20150111927A1 (en) 2015-04-23
ES2845560T3 (es) 2021-07-27
AR090544A1 (es) 2014-11-19
ZA201405938B (en) 2015-11-25
BR112014023530A2 (pt) 2017-07-18
CN104271136A (zh) 2015-01-07
AU2013241752A1 (en) 2014-09-25
EP2830621B1 (en) 2020-10-21
EA028984B1 (ru) 2018-01-31
IL234658B (en) 2018-02-28
IN2014DN08970A (enExample) 2015-05-22
CL2014002576A1 (es) 2015-01-23
US9795596B2 (en) 2017-10-24
GT201400206A (es) 2017-09-28
HK1200723A1 (en) 2015-08-14
EA201491787A1 (ru) 2015-01-30
KR20140138771A (ko) 2014-12-04
PH12014502168A1 (en) 2014-12-10
JP6224067B2 (ja) 2017-11-01
TW201345525A (zh) 2013-11-16
JP2015514080A (ja) 2015-05-18
WO2013144249A1 (en) 2013-10-03
NZ628596A (en) 2015-10-30
CA2866127A1 (en) 2013-10-03
SG11201405169SA (en) 2014-10-30
MX2014011682A (es) 2015-01-22
ECSP14025016A (es) 2015-09-30
EP2830621A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
IL275998B (en) Medical system
EP2916905A4 (en) MEDICAL CONNECTOR
EP2842540A4 (en) MEDICAL CONNECTOR
DK3679922T3 (da) Sprøjte
DK3656373T3 (da) Sprøjte
EP2830692A4 (en) Patient interface
EP2832391A4 (en) SYRINGE
DK3335652T3 (da) Medicinsk fastgørelseselement
EP2759249A4 (en) Endoscope system
EP2735260A4 (en) Endoscope
DK2897594T3 (da) Farmaceutisk sammensætning
EP2799000A4 (en) Borescope
CL2014003283A1 (es) Formulación farmacéutica.
EP2913076A4 (en) SYRINGE
FI20125887A7 (fi) Järjestely biosignaalin mittaamiseksi
EP2883547A4 (en) MEDICINE
EP2931176A4 (en) Medical sling
CO7091176A2 (es) Diagnóstico farmacéutico
BR302012003979S1 (pt) Configuração aplicada em fármaco
PL2922571T3 (pl) Postać farmaceutyczna zawierająca metaloporfiryny zawierające karboran
BR112014021433A2 (pt) formulações farmacêuticas
ECSP12011630A (es) Formulación farmacéutica
TH1401006714B (th) แคปซูล
FR2986420B1 (fr) Pillulier
EP2885023A4 (en) SYRINGE